CANNABIS COMPOSITION

1 . A pharmaceutical composition comprising a Cannabis extract and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof, the Cannabis extract comprising a cannabinoid fraction and a terpene fraction, wherein the Cannabis extract comprises either:

A:

≥0.3% w/w of the terpene fraction;

≥50% w/w Δ 9 -Tetrahydrocannabinol (THC);

≥0.3% w/w Cannabigerol (CBG); and

≤0.5% w/w Cannabinodiol (CBN).

or

B:

≥0.5% w/w of the terpene fraction;

≥60% w/w CBD;

≤3% w/w THC; and

≤0.1% w/w CBN;

wherein the terpene fraction comprises:

β-caryophyllene in an amount of at least 11% by weight of the terpene fraction, and

one or more of:

linalool in an amount of at least 5% by weight of the terpene fraction; and

β-pinene in an amount of at least 1% by weight of the terpene fraction.

2 . The pharmaceutical composition according to claim 1 , wherein the Cannabis extract is a Cannabis oil.

3 . The pharmaceutical composition according to claim 1 or 2 , wherein the Cannabis extract comprises Δ 9 -tetrahydrocannabinol (THC) in an amount of from 50% to 99% by weight of the pharmaceutical composition.

4 . The pharmaceutical composition according to claim 1 or 2 , comprising cannabidiol (CBD) in an amount of from 60% to 99% by weight of the pharmaceutical composition.

5 . The pharmaceutical composition according to any one of claims 1 to 4 , wherein the Cannabis extract comprises one or more additional cannabinoids selected from Δ 9 -Tetrahydrocannabinolic acid (THCA), Δ 9 -Tetrahydrocannabivarin (THCV), and (-)-Cannabidivarin (CBDV).

6 . The pharmaceutical composition according to any one of claims 1 to 5 , wherein the terpene fraction comprises both linalool and β-pinene.

7 . The pharmaceutical composition according to any one of claims 1 to 6 , wherein the terpene fraction further comprises one or more of β-myrcene, D-limonene, a nerolidol and α-pinene.

8 . The pharmaceutical composition according to any one of claims 1 to 7 , wherein the terpene fraction further comprises one or more of oc-bisabolol, caryophyllene oxide, p-cymene, isopulegol, ocimene, α-terpinene, γ-terpinene, δ-s-carene, guaiol, and terpinolene.

9 . The pharmaceutical composition according to any one of claims 1 to 8 , wherein the pharmaceutically acceptable carrier is sesame oil.

10 . The pharmaceutical composition according to any one of claims 1 to 9 , further comprising an active agent other than the Cannabis extract.

11 . A method for treating cancer or a symptom associated with cancer, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to any one of claims 1 to 10 .

12 . The method according to claim 11 , wherein the cancer is breast cancer.

13 . The method according to claim 12 , wherein the cancer is selected from HER2 positive, triple negative and hormone receptor positive breast cancer.

14 . Use of a Cannabis extract in the preparation of a medicament for treating cancer or a symptom associated with cancer, wherein the Cannabis extract comprises a cannabinoid fraction and a terpene fraction, and wherein the Cannabis extract comprises either:

A:

≥0.3% w/w of the terpene fraction;

≥50% w/w Δ 9 -Tetrahydrocannabinol (THC);

≥0.3% w/w Cannabigerol (CBG); and

≤0.5% w/w Cannabinodiol (CBN).

or

B:

≥0.5% w/w of the terpene fraction;

≥60% w/w CBD;

≤3% w/w THC; and

≤0.1% w/w CBN.

15 . The use of claim 14 , wherein the terpene fraction comprises:

β-caryophyllene in an amount of at least 11% by weight of the terpene fraction, and

one or more of:

linalool in an amount of at least 5% by weight of the terpene fraction; and

β-pinene in an amount of at least 1% by weight of the terpene fraction.

16 . The pharmaceutical composition according to any one of claims 1 to 10 for treating cancer or a symptom associated with cancer.